Paul D. Smith

Queen Mary University of London — United Kingdom

Medicine · Health Sciences

57h-index13.5kcitations273works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(64), Computational Drug Discovery Methods(60), PI3K/AKT/mTOR signaling in cancer(42), Melanoma and MAPK Pathways(40), Biosimilars and Bioanalytical Methods(23)

Publications271 total

BS42 Mechanical imprinting of the talin interaction with DLC1 regulates RHOA activity and cardiomyocyte remodelling
2025Open Access
P279 Follow up and recurrence in upper tract urothelial carcinoma after radical nephroureterectomy: A multi-centre 5 yr audit
European Urology Open Science·2024Open Access
Figure S3 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
2024Open Access
Table S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
2024Open Access
Figure S5 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
2024Open Access
Figure S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
2024Open Access
Data from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
2024Open Access
Figure S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
2024Open Access
Figure S3 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
2024Open Access
Figure S5 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
2024Open Access
Figure S2 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
2024Open Access
Data from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
2024Open Access
Figure S4 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
2024Open Access
Figure S4 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
2024Open Access
Figure S2 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
2024Open Access
Table S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
2024Open Access
Table S16 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024Open Access
Table S9 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024Open Access
Table S15 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024Open Access
Figure 3 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
2024Open Access
page 1 of 14Next →

Frequent Co-authors

Simon J. Cook(5), Wolf Reik(5), Barry R. Davies(5), Jonathan R. Dry(5), Matthew J. Sale(4), Wendy Dean(4), Armelle Logié(4), Robert W. Wilkinson(4), Pasi A. Jänne(3), Lucio Crinò(3), Elaine Kilgour(3), Susan E. Critchlow(3), Colin P. Sibley(3), Christine M. Chresta(3), Sylvie M. Guichard(3), Alice T. Shaw(2), José Rodrigues Pereira(2), G. Jeannin(2), Johan Vansteenkiste(2), Fábio Franke(2)